(DDS) Dillard's - Ratings and Ratios
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US2540671011
Apparel, Accessories, Cosmetics, Home-Furnishings, Footwear
Dividends
| Dividend Yield | 0.95% |
| Yield on Cost 5y | 16.22% |
| Yield CAGR 5y | 156.57% |
| Payout Consistency | 94.2% |
| Payout Ratio | 2.4% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 41.6% |
| Value at Risk 5%th | 60.6% |
| Relative Tail Risk | -11.42% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.30 |
| Alpha | 51.68 |
| CAGR/Max DD | 0.83 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.456 |
| Beta | 1.082 |
| Beta Downside | 0.818 |
| Drawdowns 3y | |
|---|---|
| Max DD | 42.02% |
| Mean DD | 13.90% |
| Median DD | 13.20% |
Description: DDS Dillard's November 06, 2025
Dillards, Inc. (NYSE: DDS) operates a network of department stores across the southeastern, southwestern and mid-Midwestern United States, selling apparel, accessories, cosmetics, home furnishings and other consumer goods both in-store and online via dillards.com, with additional clearance-center locations.
As of the most recent fiscal quarter, Dillards reported comparable-store sales growth of 2.8% year-over-year and an operating margin of roughly 7.5%, while maintaining a debt-to-EBITDA ratio near 2.2×, indicating modest leverage relative to peers.
The companys performance is closely tied to discretionary consumer spending trends, which are influenced by household income growth, inflationary pressure on apparel prices, and the competitive dynamics of e-commerce platforms that continue to erode foot traffic in brick-and-mortar retail.
For a deeper, data-driven look at how these factors translate into valuation risk and upside, you may find ValueRay’s analytical dashboards worth exploring.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (580.9m TTM) > 0 and > 6% of Revenue (6% = 397.5m TTM) |
| FCFTA 0.18 (>2.0%) and ΔFCFTA 1.93pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 26.01% (prev 25.47%; Δ 0.55pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.20 (>3.0%) and CFO 867.2m > Net Income 580.9m (YES >=105%, WARN >=100%) |
| Net Debt (-600.6m) to EBITDA (926.7m) ratio: -0.65 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.19 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (15.6m) change vs 12m ago -3.11% (target <= -2.0% for YES) |
| Gross Margin 38.88% (prev 40.96%; Δ -2.09pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 157.2% (prev 162.0%; Δ -4.88pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -517.6 (EBITDA TTM 926.7m / Interest Expense TTM -1.45m) >= 6 (WARN >= 3) |
Altman Z'' 11.43
| (A) 0.40 = (Total Current Assets 3.17b - Total Current Liabilities 1.45b) / Total Assets 4.30b |
| (B) 1.45 = Retained Earnings (Balance) 6.23b / Total Assets 4.30b |
| warn (B) unusual magnitude: 1.45 — check mapping/units |
| (C) 0.18 = EBIT TTM 751.1m / Avg Total Assets 4.22b |
| (D) 2.74 = Book Value of Equity 6.18b / Total Liabilities 2.25b |
| Total Rating: 11.43 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 73.05
| 1. Piotroski 6.0pt |
| 2. FCF Yield 8.89% |
| 3. FCF Margin 11.74% |
| 4. Debt/Equity 0.27 |
| 5. Debt/Ebitda -0.65 |
| 6. ROIC - WACC (= 14.83)% |
| 7. RoE 30.50% |
| 8. Rev. Trend -35.32% |
| 9. EPS Trend -52.84% |
What is the price of DDS shares?
As of December 06, 2025, the stock is trading at USD 698.18 with a total of 113,149 shares traded.
Over the past week, the price has changed by +4.20%, over one month by +13.58%, over three months by +21.07% and over the past year by +67.68%.
Over the past week, the price has changed by +4.20%, over one month by +13.58%, over three months by +21.07% and over the past year by +67.68%.
Is DDS a buy, sell or hold?
Dillard's has received a consensus analysts rating of 2.00.
Therefor, it is recommend to sell DDS.
- Strong Buy: 0
- Buy: 0
- Hold: 1
- Sell: 1
- Strong Sell: 1
What are the forecasts/targets for the DDS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 431.7 | -38.2% |
| Analysts Target Price | 431.7 | -38.2% |
| ValueRay Target Price | 961.2 | 37.7% |
DDS Fundamental Data Overview November 23, 2025
Market Cap USD = 9.54b (9.54b USD * 1.0 USD.USD)
P/E Trailing = 16.6095
P/E Forward = 32.0513
P/S = 1.4399
P/B = 4.5506
P/EG = -1.28
Beta = 1.3
Revenue TTM = 6.63b USD
EBIT TTM = 751.1m USD
EBITDA TTM = 926.7m USD
Long Term Debt = 521.6m USD (from longTermDebt, last fiscal year)
Short Term Debt = 106.0m USD (from shortTermDebt, last quarter)
Debt = 548.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -600.6m USD (from netDebt column, last quarter)
Enterprise Value = 8.75b USD (9.54b + Debt 548.6m - CCE 1.33b)
Interest Coverage Ratio = -517.6 (Ebit TTM 751.1m / Interest Expense TTM -1.45m)
FCF Yield = 8.89% (FCF TTM 778.0m / Enterprise Value 8.75b)
FCF Margin = 11.74% (FCF TTM 778.0m / Revenue TTM 6.63b)
Net Margin = 8.77% (Net Income TTM 580.9m / Revenue TTM 6.63b)
Gross Margin = 38.88% ((Revenue TTM 6.63b - Cost of Revenue TTM 4.05b) / Revenue TTM)
Gross Margin QoQ = 41.24% (prev 34.64%)
Tobins Q-Ratio = 2.04 (Enterprise Value 8.75b / Total Assets 4.30b)
Interest Expense / Debt = -0.42% (Interest Expense -2.30m / Debt 548.6m)
Taxrate = 23.10% (39.0m / 168.8m)
NOPAT = 577.5m (EBIT 751.1m * (1 - 23.10%))
Current Ratio = 2.19 (Total Current Assets 3.17b / Total Current Liabilities 1.45b)
Debt / Equity = 0.27 (Debt 548.6m / totalStockholderEquity, last quarter 2.05b)
Debt / EBITDA = -0.65 (Net Debt -600.6m / EBITDA 926.7m)
Debt / FCF = -0.77 (Net Debt -600.6m / FCF TTM 778.0m)
Total Stockholder Equity = 1.90b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.51% (Net Income 580.9m / Total Assets 4.30b)
RoE = 30.50% (Net Income TTM 580.9m / Total Stockholder Equity 1.90b)
RoCE = 30.96% (EBIT 751.1m / Capital Employed (Equity 1.90b + L.T.Debt 521.6m))
RoIC = 24.27% (NOPAT 577.5m / Invested Capital 2.38b)
WACC = 9.44% (E(9.54b)/V(10.09b) * Re(10.0%) + D(548.6m)/V(10.09b) * Rd(-0.42%) * (1-Tc(0.23)))
Discount Rate = 10.0% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.40%
[DCF Debug] Terminal Value 69.65% ; FCFE base≈734.2m ; Y1≈667.2m ; Y5≈584.5m
Fair Price DCF = 660.2 (DCF Value 7.67b / Shares Outstanding 11.6m; 5y FCF grow -11.38% → 3.0% )
EPS Correlation: -52.84 | EPS CAGR: -16.91% | SUE: 1.19 | # QB: 1
Revenue Correlation: -35.32 | Revenue CAGR: -9.34% | SUE: 1.69 | # QB: 1
EPS next Quarter (2026-04-30): EPS=9.24 | Chg30d=-0.040 | Revisions Net=+1 | Analysts=1
EPS next Year (2027-01-31): EPS=27.92 | Chg30d=+2.330 | Revisions Net=+1 | Growth EPS=-14.1% | Growth Revenue=-1.6%
P/E Trailing = 16.6095
P/E Forward = 32.0513
P/S = 1.4399
P/B = 4.5506
P/EG = -1.28
Beta = 1.3
Revenue TTM = 6.63b USD
EBIT TTM = 751.1m USD
EBITDA TTM = 926.7m USD
Long Term Debt = 521.6m USD (from longTermDebt, last fiscal year)
Short Term Debt = 106.0m USD (from shortTermDebt, last quarter)
Debt = 548.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -600.6m USD (from netDebt column, last quarter)
Enterprise Value = 8.75b USD (9.54b + Debt 548.6m - CCE 1.33b)
Interest Coverage Ratio = -517.6 (Ebit TTM 751.1m / Interest Expense TTM -1.45m)
FCF Yield = 8.89% (FCF TTM 778.0m / Enterprise Value 8.75b)
FCF Margin = 11.74% (FCF TTM 778.0m / Revenue TTM 6.63b)
Net Margin = 8.77% (Net Income TTM 580.9m / Revenue TTM 6.63b)
Gross Margin = 38.88% ((Revenue TTM 6.63b - Cost of Revenue TTM 4.05b) / Revenue TTM)
Gross Margin QoQ = 41.24% (prev 34.64%)
Tobins Q-Ratio = 2.04 (Enterprise Value 8.75b / Total Assets 4.30b)
Interest Expense / Debt = -0.42% (Interest Expense -2.30m / Debt 548.6m)
Taxrate = 23.10% (39.0m / 168.8m)
NOPAT = 577.5m (EBIT 751.1m * (1 - 23.10%))
Current Ratio = 2.19 (Total Current Assets 3.17b / Total Current Liabilities 1.45b)
Debt / Equity = 0.27 (Debt 548.6m / totalStockholderEquity, last quarter 2.05b)
Debt / EBITDA = -0.65 (Net Debt -600.6m / EBITDA 926.7m)
Debt / FCF = -0.77 (Net Debt -600.6m / FCF TTM 778.0m)
Total Stockholder Equity = 1.90b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.51% (Net Income 580.9m / Total Assets 4.30b)
RoE = 30.50% (Net Income TTM 580.9m / Total Stockholder Equity 1.90b)
RoCE = 30.96% (EBIT 751.1m / Capital Employed (Equity 1.90b + L.T.Debt 521.6m))
RoIC = 24.27% (NOPAT 577.5m / Invested Capital 2.38b)
WACC = 9.44% (E(9.54b)/V(10.09b) * Re(10.0%) + D(548.6m)/V(10.09b) * Rd(-0.42%) * (1-Tc(0.23)))
Discount Rate = 10.0% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.40%
[DCF Debug] Terminal Value 69.65% ; FCFE base≈734.2m ; Y1≈667.2m ; Y5≈584.5m
Fair Price DCF = 660.2 (DCF Value 7.67b / Shares Outstanding 11.6m; 5y FCF grow -11.38% → 3.0% )
EPS Correlation: -52.84 | EPS CAGR: -16.91% | SUE: 1.19 | # QB: 1
Revenue Correlation: -35.32 | Revenue CAGR: -9.34% | SUE: 1.69 | # QB: 1
EPS next Quarter (2026-04-30): EPS=9.24 | Chg30d=-0.040 | Revisions Net=+1 | Analysts=1
EPS next Year (2027-01-31): EPS=27.92 | Chg30d=+2.330 | Revisions Net=+1 | Growth EPS=-14.1% | Growth Revenue=-1.6%
Additional Sources for DDS Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle